Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric ozanimod study in moderately to severely active ulcerative colitis
2021-002308-11Phase 2Active
- Sponsor
- Celgene Corporation
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ozanimod in autoimmune colitis (2 arms), sponsored by Celgene Corporation. Primary endpoints: Clinical remission at Week 52 and Clinical remission at Week 10. Started Oct 2021; status: active.
02
Drugs
ozanimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2021-002308-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002308-11.